Judee Sharon

Judee Sharon is a Cal alumna with a Ph.D. from the University of Minnesota. She is currently Co-founder and CEO of KuriBio, an early stage biotech company. At KuriBio, Judee has developed a nanotech-based platform for early detection of cancers that are typically detected at later stages and that have a high mortality rate, such as pancreatic cancers. Her technology is based on liposomal nanoparticles that quantitatively indicate the presence of a growing tumor. Judee envisions being able to multiplex her platform for concurrent detection of various cancers in one single test. The WIES fellowship will provide Judee with business mentorship, lab space, and funds for additional R&D to de-risk her technology.

Mimi Guo

Mimi Guo is currently a postdoc in the Schaffer lab at UC Berkeley, where she engineers new AAV for enhanced gene delivery in the central nervous system. Mimi has a diverse educational background, including prior experience in mechanical engineering. Her goal is to develop therapeutic approaches for neurological diseases by evolving AAV to genetically manipulate specific cell types in the CNS. During the WIES fellowship year, Mimi aims to identify and optimize AAV variants through directed evolution and machine learning. She will also work on developing therapeutic payloads and validate their effects on human brain samples. Successful completion of the project will yield new treatment strategies for neurological diseases.

Carlotta Ronda

Carlotta Ronda is an IGI Investigator on the microbiome editing team. Her proposal is centered around her demonstrated expertise in editing microbes, and her idea of developing therapies for eye diseases by editing microbes already present in the eye microbiome to continuously deliver therapeutic molecules to the eye's surface. The first product coming out of her platform would be a therapy for glaucoma. In the WIES fellowship year Carlotta would develop an early proof-of-concept of the ocular microbiome editing technique using fluorescent reporters to demonstrate editing capacity while also optimizing delivery methods of engineered microbes for stable colonization of the eye.

Julia Turnšek

Julia Turnšek has recently completed her Ph.D. in the Savage lab at the IGI, where she is currently an HHMI postdoctoral fellow. Julia is in the ideation stage of her project and is looking to break into the multi-billion dollar fertilizer market for the agriculture industry. Current phosphorus fertilizer is mined from rock (which is extremely polluting and damaging to the environment). She envisions creating an enzymatic soil amendment to unlock phosphorus (phosphate) which currently exists in the soil, but in forms that are inaccessible to plants. Enzymatic amendments would eliminate the need for phosphorus fertilizer inputs, and would also contribute to reducing fertilizer overuse, which is costly and polluting. She believes the WIES program would be a perfect venue to generate proof-of-concept data, and to gain entrepreneurial and business acumen.

Derfogail Delcassian

Derfogail Delcassian is an Assistant Professor in the Department of Bioengineering at UC Berkeley. She is developing a new approach for long-term genetic reprogramming using mRNA for transient protein expression to regulate the epigenome. As a WIES fellow, she plans to pilot her idea using a melanoma model to understand how tumor immune cell behavior changes following receiving mRNA that encodes epigenetic modifying enzymes. In this study, Delcassian will examine the role of macrophages in the immune response to cancer. If successful, this would be a new platform technology bridging the gap between the transient nature of mRNA therapeutics and the permanence of genome editing and could be used to treat many diseases and apply to a number of fields including tumor biology and immunology. 

Yue Clare Lou

Yue Clare Lou is currently completing her Ph.D. in the laboratory of Jill Banfield, Director of Microbiology at the IGI, before starting her fellowship in Fall. Lou studies the relationship between the gut microbiome and infant health. She recently led the development of a gut microbiome diagnostic platform and has published a proof-of-concept preprint in which she demonstrated that functional predictions from metagenomic analyses of infant microbiomes could be tested and recreated experimentally using cultivated microbiomes. Specifically, her work describes how microbial communities, which are specific to each individual, work together to metabolize oligosaccharides in human milk. Her work emphasizes the importance of supplementing individualized interventions as each infant (and also adult!) is colonized by a unique collection of gut microbes. As a WIES fellow, Clare will expand the platform she developed to identify additional infant gut microbial markers that can be leveraged to guide personalized microbiome interventions. Learn more about Clare in our Meet an IGI Scientist profile. 

Alice Refermat

Alice Refermat is currently the Director of the Center for CRISPR Target Discovery at the IGI. She co-invented a platform technology, ZFPOFF, for heritable epigenetic gene repression using artificial zinc-finger proteins. As a WIES fellow, she proposes to use this technology to develop a treatment for KRAS-based cancers. Alterations in the KRAS gene are found in 23 percent of all adult cancers, including a high percentage of lung, pancreatic, and colorectal cancers. Several cancer-causing mutations in KRAS still have no specific drug available, leaving patients with limited treatment options. If successful, Refermat believes this technology could be translated to treat other cancers associated with other cancer-driving genes that currently lack specific treatments. Learn more about Alice in our Meet an IGI Scientist profile.

Kelsey Hern

Kelsey Hern is currently completing her Ph.D. in Prof. Adam Arkin’s lab at UC Berkeley before starting her fellowship in Fall. Hern is working on the identification of airway microbiome constituents that require only a single dose to stably colonize the lung and act as probiotics by preventing death from respiratory infections. As a WIES fellow, she proposes to build on her dissertation work to develop a platform that will enable the prevention and continuous monitoring of various respiratory diseases. She plans to pilot this idea in lung cancer. Hern is excited to be colleagues with the team at IGI’s Berkeley Initiative for Optimized Microbiome Editing (BIOME), which will be extremely beneficial to achieving her goals. Learn more about Kelsey in our Meet an IGI Scientist profile. 

Follow along with the WIES Fellows and how they are progressing on the IGI's social media channels (see bottom of page for links).

Navneet Matharu

Navneet Matharu is an assistant professor in the Department of Bioengineering and Therapeutic Sciences, the Institute for Human Genetics, and School of Pharmacy at UC San Francisco, and is a co-founder of Regel Therapeutics, a gene therapy startup based in Berkeley, CA and Cambridge, MA. As a WIES fellow, Matharu is working to target genetic diseases caused by gene dosage defects, where a copy of a gene is inactivated or deleted, resulting in physiological symptoms. Gene dosage effects on the X chromosome disproportionately affect women. Matharu’s previous work provided a proof of concept approach to addressing gene dosage effects using CRISPR, and she will further develop this approach during her WIES fellowship. Learn more about Navneet here.

Jenny Hamilton 

Jenny Hamilton is a former postdoc in the Doudna lab at the University of California, Berkeley where she worked to develop novel approaches for delivering CRISPR-based genome editing tools. Hamilton’s project for the WIES fellowship is exploring a new method of improving targeted genome engineering in humans using CRISPR. Currently, CRISPR therapies can be limited by our ability to deliver genome editing tools to disease-relevant cell types. Hamilton’s work builds on her research on enveloped delivery vehicles (EDVs), where she has demonstrated the ability to target delivery of genome-editing molecules by harnessing the natural abilities of viruses. Precise, in-vivo delivery of CRISPR to specific cells and tissues will further enable new human therapies and lower the cost of treatment. Learn more about Jenny here.

Lin Du

Lin Du is an assistant professor at the Ohio State University in the College of Medicine and College of Engineering, and formerly a postdoc in the Department of Electrical Engineering and Computer Sciences at the University of California, Berkeley, where she worked on scalable fabrication of biosensor arrays. For Du’s WIES fellowship, she worked on developing synthetic DNA biosensors for precise detection of hundreds of species of viruses simultaneously using aptamers. Aptamers are synthetic nucleic acids used for detection and capture that can be rapidly and reliably designed, optimized for both diagnostics and therapeutic purposes. Aptamer-based platforms could prove to be transformative and broadly applicable in detection and monitoring of infectious diseases, as well as potentially transferable to other medical and environmental applications. Learn more about Lin here.